Monitor for upcoming clinical trial initiation of CUE-401 in H2 2026 and any follow-on financing activity, given the company's going concern warning and small market cap. Leadership continuity under Warren may stabilize investor sentiment short-term.
Price Chart
Executive Summary
Cue Biopharma appointed Lucinda Warren as interim president and CEO following the departure of Usman Azam. Warren, previously CFO and chief business officer, has a strong business development background, including key deals for CUE-401 and collaborations with Boehringer Ingelheim and ImmunoScape. The leadership change is framed as a transition, with focus on advancing CUE-401 into clinical trials by late 2026.
Key Facts
- Lucinda Warren appointed interim president and CEO of Cue Biopharma effective March 26, 2026.
- Usman Azam stepped down as president, CEO, and board member.
- Warren previously served as CFO and chief business officer, with over 30 years of biopharma experience, including at Johnson & Johnson and Janssen.
- She led key strategic transactions: return of CUE-401 rights, Boehringer Ingelheim collaboration on CUE-501, and ImmunoScape partnership on solid tumor cell therapy.
- Company plans to advance CUE-401 into the clinic in the second half of 2026.
- Forward-looking statements highlight risks including going concern, financing needs, and clinical development uncertainty.
Financial Impact
No immediate financial impact disclosed; leadership transition may affect execution risk.
Risk Factors
- Company faces going concern risk due to limited cash and history of losses.
- Clinical development setbacks could delay or derail CUE-401 progress.
- Interim CEO status may create uncertainty around long-term strategy.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264084 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | Insider Cluster | $18.67 $16.71 | ▲ +10.50% | ▲ +9.39% | $18.45 (+1.18%) |
Oct 13, 2026 13d ago | 144 | $18.60 $18.67 | ▲ +0.38% | ▲ +0.09% | $18.45 (−0.81%) |
Oct 8, 2026 18d ago | SC 13G/A | $22.33 $27.66 | ▲ +23.87% | ▲ +23.27% | $18.45 (−17.38%) |
Sep 21, 2026 5w ago | 8-K | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.45 (−34.74%) |
Sep 20, 2026 5w ago | Press Release | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.45 (−34.74%) |
Aug 21, 2026 9w ago | EFFECT | $23.98 $23.18 | ▲ +3.34% | ▲ +3.04% | $18.45 (+23.06%) |
Aug 17, 2026 10w ago | Insider Cluster | $25.70 $26.28 | ▼ −2.26% | ▼ −2.05% | $18.45 (+28.21%) |
Aug 14, 2026 10w ago | Press Release | $27.64 $25.70 | ▼ −7.02% | ▼ −6.34% | $18.45 (−33.25%) |
Aug 13, 2026 10w ago | 144 | $34.20 $27.64 | ▼ −19.18% | ▼ −18.71% | $18.45 (−46.05%) |
Jul 9, 2026 15w ago | Press Release | $36.78 $30.92 | ▼ −15.93% | ▼ −15.17% | $18.45 (−49.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers